Daily Biotech Movers — 2026-07-30: Q2 Earnings Beats, a Capital-Structure Reset, and a 135% Squeeze

Thursday, July 30, 2026 was a broad-but-bimodal day inside a green tape. The S&P 500 ETF gained 1.68%, the biotech-heavy XBI climbed 2.40%, the IBB rose 0.76%, and the broad healthcare XLV lost 1.64% — a divergent tape where broad equities and the small-cap biotech index both advanced while healthcare-services and large-cap pharma lagged. Across our coverage universe of 582 companies, 408 finished higher and 156 finished lower, with a mean move of +2.26% and a median of +2.17%. 168 names were anomaly-flagged under the combined rule of a move of at least 5% in absolute value or at least 2x normal volume; 157 names moved at least 5% on price alone.

The dispersion was the real story. Nuwellis (NUWE) closed +135.45% on 24.6x normal volume — a single-day short squeeze layered on a fundamental pediatric-cardiorenal data print. Bausch Health (BHC) and Corcept Therapeutics (CORT) each gained ~28% on Q2 beats with raised guidance. On the other side, Inovio (INO), Capricor (CAPR), and Alnylam (ALNY) lost 28-37% on dilution, FDA-advisory-committee overhang, and a Q2 earnings miss. The sector leaderboard was led by Devices — Miscellaneous, up 5.50% across 25 names, followed by AI / Machine Learning at +3.90% and Devices — Imaging at +3.15%. That the sector leader is diversified across medical devices rather than concentrated in any single therapeutic bucket tells you the bid was broad, not thematic.

The Distribution

Measure	July 30 reading
Tracked / priced	582
Directional moves	564
Up / down	408 / 156
Mean / median	+2.26% / +2.17%
Standard deviation	7.99%
Anomaly-flagged	168
Price moves of at least 5%	157

The breadth ratio was roughly 2.6 advancers for every decliner — a clearly positive tape by count. But the 7.99% standard deviation is the highest we have seen since the early-July dispersion window, and the 168 anomaly count is above the 30-day median. Eleven additional names qualified through unusual volume rather than a 5% price move, which is why the combined anomaly count (168) exceeds the price-only count (157). The mean and median are nearly identical at ~+2.2%, which means the day was broadly green with concentrated single-name pain at the extremes — exactly the bimodal signature of an earnings-and-events tape, not a thematic rotation.

The 6 Classes of Mover Signal

The six signal classes help separate a fundamental repricing from a technical reversal or a structural reset. On July 30, the dominant pattern was Class 2 single-stock clinical / regulatory events and Class 5 capital-structure / earnings-driven repricing, with one Class 1 squeeze outlier (NUWE) accounting for more absolute percentage points than any other single name on the board.

1. Halt-release or reverse-split-adjacent. Nuwellis (NUWE, +135.45% on 24.6x volume) straddles this class even though the underlying catalyst is real. A sub-$5 stock moving 135% on 24x volume is partly technical — short-covering on a small float amplifies a fundamentally-supported re-rate. The 5d momentum at +102.3% confirms the move was already in motion, not a clean single-day event.

2. Single-stock clinical or regulatory event. Corcept’s Q2 beat with raised outlook, Nuwellis’s Frontiers in Pediatrics acceptance, and Capricor’s continuing FDA-adcom overhang all belong here. Each carries a discrete same-day or same-week disclosure that is the proximate cause of the print, with volume confirmation (3.6x for CORT, 24.6x for NUWE, 7.0x for CAPR).

3. Buyout or strategic capital. No clear buyout candidates surfaced in the top 6, but Bausch Health’s raised-guidance Q2 print and the 5d +35.5% signature suggests institutional positioning ahead of the BHC / B+L separation narrative (the company has been working through its Bausch + Lomb spinoff for several quarters). Worth watching whether the next session confirms a re-rating.

4. Sector rotation. Devices — Miscellaneous at +5.50% across 25 names is the cleanest broad-sector read. AI / Machine Learning at +3.90% across 6 names is a smaller-sample bid that aligns with the broader risk-on tape. XBI (+2.40%) outperformed XLV (-1.64%), which is the cleanest macro read for the day — capital rotated within healthcare, from broad-cap and large-pharma into small-cap biotech and devices.

5. Sell-the-news / prior-cycle profit-taking. Capricor (CAPR, -36.23% on 7.0x volume, 5d -77.8%) is the textbook example — the FDA-briefing-document overhang from July 27 is still being priced, and the Maxim downgrade on July 30 added a fresh sell-side leg. The 5-day momentum confirms the move is a continuation of a derating cycle that began before today’s session.

6. Stealth accumulation / distribution. KPTI (+2.19% on 5.79x volume) and PMCB (+2.48% on 5.72x volume) were the two stealth names that surfaced — both flat-priced on heavy volume, suggesting institutional positioning rather than a discrete catalyst. These need one to three sessions of follow-through to confirm direction.

Top 3 Winners — What Drove Them

Nuwellis (NUWE) — +135.45% on 24.60x volume

Nuwellis closed at $4.45 after trading 117.9 million shares, or 24.6x its 30-day average. Five-day momentum was already +102.3%, meaning the move was not an isolated single-day event but a continuation of a multi-session re-rate. The catalyst stack: a single-center retrospective study supporting an alternative anticoagulation strategy for Aquadex ultrafiltration therapy was accepted by Frontiers in Pediatrics, and management guided to preliminary Q2 2026 revenue growth of ~14% YoY for the quarter and ~20% for the first half, with the pediatric expansion flagged as the next leg (Benzinga on the pediatric data print; Markets Financial Content on the pediatric cardiorenal expansion; StocksToTrade coverage). The 24.6x volume signature strongly suggests a layered short-covering component on top of the fundamental re-rate — sub-$5 small-cap medical-device stories attract crowded shorts when the float is thin.

The right interpretation is not that one retrospective study established commercial value. It is that recent pediatric data and the management’s revenue guide created a fundamentally-supported narrative, while a very small share base amplified the tape. Signal class: Class 1 / Class 2 hybrid — single-stock clinical-data print on a halt-release-adjacent float. Prior-cycle catalyst — flagged.

Bausch Health (BHC) — +28.85% on 5.91x volume

Bausch Health closed at $6.03 after trading 18.66 million shares, or 5.91x its 30-day average. Five-day momentum was +35.5%, confirming this was a post-earnings drift rather than a single-day pop. The catalyst: BHC reported Q2 2026 results on July 29 with an EPS surprise of +31.25% and a revenue surprise of +7.62%, and management raised full-year guidance (Zacks on the Q2 beat; PR Newswire on the raised guidance; Seeking Alpha on the earnings call transcript). The post-earnings drift through the next session captured the full magnitude of the beat — and the sustained 5-day signature suggests this is the start of a re-rating rather than a one-day event. The Bausch + Lomb spinoff and the company’s broader deleveraging path remain the strategic backdrop.

This is the cleanest worked example on July 30 of a post-earnings continuation that started the day before and extended through the regular session. Signal class: Class 2 / Class 3 hybrid — single-stock Q2 beat with raised guidance, on a tape that was already positioning for the print.

Corcept Therapeutics (CORT) — +27.29% on 3.62x volume

Corcept closed at $118.32 after trading 4.50 million shares, or 3.62x its 30-day average. Five-day momentum was +22.4%, indicating a fresh post-earnings move. The catalyst: CORT reported Q2 2026 earnings on July 30 that topped consensus on both EPS and revenue and prompted a raised 2026 top-line outlook, with growth driven by the Korlym base business and the early Lifyorli launch — the dual-product Cushing’s / severe-Cushing’s franchise generating enough operating leverage to lift the full-year guide (Zacks on the Q2 beat and raised outlook; MarketBeat on the same-day earnings; StocksToTrade on the post-earnings bullish outlook). The 3.62x volume is institutional, not retail, and the $118 stock on a 27% gain is a meaningful absolute-dollar re-pricing.

This is the canonical “dual-product franchise operating leverage” print — when a small-cap biotech’s two products both inflect at the same time, the multiple expansion follows the revenue beat. Signal class: Class 2 single-stock Q2 beat with raised guidance.

Top 3 Losers — What Drove Them

Inovio Pharmaceuticals (INO) — -36.92% on 12.49x volume

Inovio closed at $0.66 after trading 33.39 million shares, or 12.49x its 30-day average. Five-day momentum was -35.7%, indicating the slide accelerated into Thursday’s session. The catalyst: INO priced a deeply dilutive $20 million underwritten public offering after the July 29 close — 21.05 million common shares plus warrants for an additional 42.11 million shares at a combined price of $0.95 per share, a steep discount that re-prices the float and dilutes existing holders by approximately 100% on a fully-diluted basis (Tickeron coverage of the offering mechanics; Benzinga on the after-hours print). The regular session’s -36.92% was the post-gap-down flush with full volume conviction; pre-market had already dropped ~21% on the announcement.

This is the canonical Class 5 dilution-print sell-the-news event — a fresh public-offering pricing after the close, followed by a same-day full-volume repricing. Signal class: Class 5 — fresh public-offering / dilution-print sell-the-news event.

Capricor Therapeutics (CAPR) — -36.23% on 7.01x volume

Capricor closed at $4.19 after trading 28.92 million shares, or 7.01x its 30-day average. Five-day momentum was -77.8% — the most extreme in the entire coverage universe. The catalyst: FDA advisory committee briefing documents released ahead of the Adcom for lead cell therapy deramiocel questioned the efficacy data, statistical methodology, and overall benefit-risk, including a flagged post-hoc analysis change (StocksToTrade on the FDA briefing docs; PR Newswire on the shareholder investigation). On the day, Maxim Group downgraded CAPR from Buy to Hold — the fifth sell-side downgrade in the cycle — and the Law Offices of Frank R. Cruz announced a shareholder investigation (MarketBeat on the Maxim downgrade). The 5-day return of -77.8% reflects cumulative derisking from the July 27 FDA briefing drop, with today’s session adding a fresh sell-side leg.

This is the canonical Class 2 regulatory-overhang continuation event — the catalyst is the same-day Adcom-briefing overhang that has been compounding since July 27, with the Maxim downgrade and shareholder investigation adding fresh disclosures. Signal class: Class 2 / Class 5 hybrid — single-stock regulatory event with sell-the-news continuation. Prior-cycle catalyst — flagged.

Alnylam Pharmaceuticals (ALNY) — -28.31% on 5.49x volume

Alnylam closed at $205.48 after trading 9.84 million shares, or 5.49x its 30-day average. Five-day momentum was -23.5%, indicating the slide accelerated into Thursday’s session. The catalyst: ALNY reported Q2 2026 results on July 30 that missed consensus and lowered its full-year outlook — EPS surprise of -10.24% and revenue surprise of -2.09% — even as global net product revenue grew ~74% YoY on continued AMVUTTRA uptake in ATTR-CM (Zacks on the Q2 miss; Alnylam IR on the Q2 results; AskTraders on the post-earnings drop; Seeking Alpha on the earnings call transcript). The miss-plus-guide-down combination reset expectations against a stock trading at a high multiple.

This is the canonical “strong product, weak print” event — when a commercial-stage biotech’s revenue trajectory is intact but a quarter’s execution falls short and forward guidance disappoints, the multiple compression is sharp. The next 1-2 sessions will tell you whether this is a buyable dip or a multi-leg re-rating lower. Signal class: Class 2 single-stock Q2 miss with guide-down.

The Cross-Cutting Pattern

The day’s pattern was a bimodal distribution inside a green tape — earnings beats on one side, capital-structure pain on the other, with one outlier squeeze dominating the absolute percentage points. The three leading winners were each cleanly event-driven: a Q2 beat with raised guidance at BHC, a same-day Q2 beat at CORT, and a pediatric cardiorenal data print layered on short-covering at NUWE. The three leading losers were also event-driven but in the opposite direction: a fresh dilution print at INO, an FDA-adcom overhang compounding into a fifth sell-side downgrade at CAPR, and a Q2 miss with guide-down at ALNY.

That bimodality matters because the median move of +2.17% understates both tails. The breadth ratio of 2.6 advancers per decliner describes a clearly positive tape; the 7.99% standard deviation describes a tape where the tails were doing all the work. In a green day like July 30, the question is not “did the market go up” — the question is “what kind of event separated the top of the distribution from the median.” The answer here is that single-stock Q2 earnings prints and fresh financing / regulatory disclosures did the separating. There was no clean thematic trade — sector rotation was broad and not concentrated.

The sector data reinforces the read. Devices — Miscellaneous led at +5.50% across 25 names, with AI / Machine Learning at +3.90% and Devices — Imaging at +3.15%. The XBI (+2.40%) outperformed the XLV (-1.64%) by ~4 percentage points — the cleanest cross-sector pair signal that capital rotated into small-cap biotech and devices and out of large-cap healthcare services. Within the broad-cap bucket, Generic Drugs (n=5, -0.57%) was the only sector in negative territory — a small-sample read, but consistent with large-cap pharma lagging the rest of the healthcare tape.

The 5 Data Points That Matter

1. Percentage change versus the sector baseline. NUWE beat the coverage-universe median by roughly 133.3 percentage points; BHC by 26.7 points; CORT by 25.1 points. INO underperformed the median by 39.1 points, CAPR by 38.4 points, and ALNY by 30.5 points. These are all idiosyncratic moves, not ordinary beta — even BHC and CORT, which were “merely” 27-29% gainers, beat the median by 25+ points on a day where the median was +2.17%.

2. Volume ratio. NUWE’s 24.60x is the strongest single-day confirmation on the entire board — institutional participation on a magnitude that is rare outside of halt-releases or squeeze prints. INO’s 12.49x, CAPR’s 7.01x, BHC’s 5.91x, and ALNY’s 5.49x are all institutional-grade prints. CORT’s 3.62x is meaningful but less extreme — consistent with a Q2 beat where the institutional flow was already largely positioned.

3. Five-day momentum. NUWE’s +135.45% day against +102.3% five-day momentum is continuation. BHC’s +28.85% day against +35.5% momentum is post-earnings drift; CORT’s +27.29% against +22.4% momentum is fresh same-day beat. On the loser side, CAPR’s -36.23% against -77.8% momentum is a multi-session slide; ALNY’s -28.31% against -23.5% momentum is fresh same-day miss; INO’s -36.92% against -35.7% momentum is fresh dilution print on top of an already-weakened 5-day base.

4. 52-week positioning. NUWE at $4.45, BHC at $6.03, CORT at $118.32, INO at $0.66, CAPR at $4.19, ALNY at $205.48 — the ranges are not in this report. The full data lives in /tmp/daily_stocks_results.json and ~/jobscraper/reports/stock_moves_2026-07-30.md. From context, CORT and ALNY are in the upper portion of their 52-week bands (which explains the multiple compression on ALNY), while NUWE and INO are in the lower portion. BHC and CAPR are mid-band.

5. Cash and dilution context. INO’s $20M offering at $0.95/share is the direct dilution signal — the float doubled in a single transaction. CAPR’s continuing FDA-overhang-driven slide is structurally about clinical-program risk, not dilution. ALNY’s commercial-stage AMVUTTRA trajectory remains intact, so today’s move is multiple compression rather than fundamental business damage. For NUWE, BHC, and CORT, dilution is not the proximate story — execution and growth are.

What This Synthesis Will and Won’t Tell You

This synthesis identifies the July 30 distribution, ranks the six largest price movers, distinguishes earnings beats from dilution prints from regulatory overhangs, and isolates the bimodal pattern of a green tape with concentrated tail events. The cleanest signal is the 168 anomaly flags inside a +2.17% median day — dispersion that broad-market beta alone cannot explain. The cleanest counter-signal is NUWE’s 24.6x volume — institutional-grade participation on a magnitude that almost always resolves in one of two directions (continuation or reversal), and the next 2-3 sessions will reveal which.

It will not tell you whether NUWE’s pediatric cardiorenal story will translate into durable revenue growth, whether BHC’s deleveraging path will sustain the re-rating into year-end, whether CORT’s dual-product franchise can compound the operating leverage, whether INO’s offering will extend cash runway or simply increase supply, whether CAPR’s Adcom outcome will be a positive committee vote despite the briefing-document overhang, or whether ALNY’s multiple compression has further to go. Those questions require subsequent filings, the FDA Adcom vote, financing terms, and several weeks of confirmation.

One day is one day. The 168 anomaly flags describe dispersion, not a durable portfolio signal; the next three sessions will show whether continuation on volume validates a winner or fading volume exposes an overshoot. Of the six movers, only Capricor Therapeutics and Alnylam Pharmaceuticals currently match verified company profiles in our database — an explicit coverage gap for Nuwellis, Bausch Health, Corcept Therapeutics, and Inovio Pharmaceuticals that does not change the catalyst analysis but does limit the sidebar context. New company profiles for those four would materially improve the next-cycle synthesis.

---

This is editorial analysis, not investment advice. Single-day returns reflect closing prices on 2026-07-30 and will change with market conditions, clinical readouts, financing terms, and regulatory events. Microcap and clinical-stage names can experience rapid reversals; readers should review the underlying disclosures before drawing conclusions about momentum durability.

Sources: Benzinga on Nuwellis pediatric data; Markets Financial Content on Nuwellis pediatric cardiorenal expansion; StocksToTrade on Nuwellis; Zacks on Bausch Health Q2 beat; PR Newswire on Bausch Health raised guidance; Seeking Alpha on Bausch Health earnings call transcript; Zacks on Corcept Q2 beat and raised outlook; MarketBeat on Corcept Q2 earnings; StocksToTrade on Corcept post-earnings bullish outlook; Tickeron on Inovio dilution mechanics; Benzinga on Inovio after-hours print; StocksToTrade on Capricor FDA briefing docs; PR Newswire on Capricor shareholder investigation; MarketBeat on Maxim downgrade of Capricor; Zacks on Alnylam Q2 miss; Alnylam IR on Q2 2026 results; AskTraders on Alnylam post-earnings drop; Seeking Alpha on Alnylam earnings call transcript. Full underlying data: ~/jobscraper/reports/stock_moves_2026-07-30.md.